Safety and Efficacy Study of CAL-101 in Patients with Previously Treated Low-grade Lymphoma

ID Number 12-1016

Principal Investigator(s)
Joshua Brody

Department(s) or Division(s)
Hematology and Medical Oncology


The purpose of this study is to see if an experimental drug named GS-1101   (previously known as CAL-101) given as a single-agent (not combined with other cancer-fighting drugs) is safe to give to people with your type of cancer and to see how it affects you and your cancer.

All cells receive internal signals to grow and survive, but sometimes these signals get out of control causing too much cell growth.  When cell growth gets out of control, cancers can develop.  GS-1101 blocks one of the signals inside the cells that may cause your type of cancer to grow and survive.  By blocking this signal, GS-1101 may reduce or prevent your type of cancer from growing and surviving.

You may qualify to take part in this research study because you have been diagnosed with low-grade B-cell lymphoma.  Lymphoma is cancer in the lymph glands which are found throughout the body and store special cells that fight infection and other diseases.  In addition to be able to participate in the study  you are at least 18 years old,  have had at least one previous treatment for your disease, your lymphoma is growing and causing you medical problems, and it can be measured by scans.

Contact Information
(212) 824-7375
(212) 824-7293

Recruiting Patients: No